KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

BeOne Medicines (ONC) Operating Expenses (2016 - 2025)

Historic Operating Expenses for BeOne Medicines (ONC) over the last 11 years, with Q3 2025 value amounting to $1.1 billion.

  • BeOne Medicines' Operating Expenses rose 1064.3% to $1.1 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $4.1 billion, marking a year-over-year increase of 1241.9%. This contributed to the annual value of $3.8 billion for FY2024, which is 1514.5% up from last year.
  • According to the latest figures from Q3 2025, BeOne Medicines' Operating Expenses is $1.1 billion, which was up 1064.3% from $1.1 billion recorded in Q2 2025.
  • In the past 5 years, BeOne Medicines' Operating Expenses ranged from a high of $1.1 billion in Q2 2025 and a low of -$1.2 billion during Q4 2021
  • Over the past 5 years, BeOne Medicines' median Operating Expenses value was $819.0 million (recorded in 2023), while the average stood at $722.3 million.
  • As far as peak fluctuations go, BeOne Medicines' Operating Expenses crashed by 29706.67% in 2021, and later skyrocketed by 14876.92% in 2022.
  • BeOne Medicines' Operating Expenses (Quarter) stood at -$1.2 billion in 2021, then soared by 148.77% to $562.2 million in 2022, then soared by 62.27% to $912.4 million in 2023, then grew by 14.72% to $1.0 billion in 2024, then increased by 0.57% to $1.1 billion in 2025.
  • Its Operating Expenses was $1.1 billion in Q3 2025, compared to $1.1 billion in Q2 2025 and $941.2 million in Q1 2025.